Continuous Glucose Monitors: Why Non-Diabetics Are Embracing Blood Sugar Tracking
Continuous glucose monitors — once the exclusive domain of diabetes management — are rapidly becoming the wellness accessory of 2026. From biohackers and longevity enthusiasts to athletes optimizing performance and everyday health-conscious consumers, people without diabetes are strapping CGMs to their arms in growing numbers. The question is whether this trend represents a genuine advance in preventive health or an expensive glimpse into data that most people don’t actually need.
How CGM Technology Works
A continuous glucose monitor is a small wearable sensor, typically worn on the upper arm, that measures interstitial glucose levels in real time — usually every one to five minutes — and transmits the data to a smartphone app. Unlike finger-prick blood glucose tests that provide a single snapshot, CGMs reveal the full glucose curve: how blood sugar rises after meals, how quickly it returns to baseline, and what happens during sleep, exercise, and periods of stress.
For the 38 million Americans with diabetes, CGMs have been transformative, replacing painful finger sticks with continuous data that enables more precise insulin dosing and dietary decisions. The two dominant players — Abbott’s Freestyle Libre and Dexcom’s G7 — have achieved remarkable accuracy and convenience, with sensors lasting 10-15 days and requiring no calibration.
The Wellness Pivot
In 2026, both Abbott and Dexcom have launched consumer-focused CGM products specifically marketed to people without diabetes. Abbott’s Lingo and Dexcom’s Stelo are over-the-counter devices that position glucose monitoring as a wellness tool — a window into metabolic health that can guide dietary choices, exercise timing, and lifestyle optimization.
The pitch is compelling. Even in people without diabetes, large glucose spikes and crashes — often triggered by refined carbohydrates and sugary foods — are associated with inflammation, energy fluctuations, and, over time, increased risk of developing insulin resistance and type 2 diabetes. By visualizing these patterns in real time, consumers can learn which foods cause problematic glucose responses and adjust their diets accordingly. Two people might eat the same banana and have dramatically different glucose responses, a phenomenon that CGMs make visible for the first time at the individual level.
Startups like Levels, January AI, and Nutrisense have built entire businesses around this concept, pairing CGM hardware with AI-powered apps that analyze glucose data and provide personalized nutrition recommendations. The market is growing rapidly, with analysts projecting the consumer CGM segment could reach several billion dollars within the next few years.
What the Evidence Says — and Doesn’t Say
Here’s where the picture gets complicated. While CGMs provide accurate glucose data, the clinical value of continuous glucose monitoring for metabolically healthy individuals remains largely unproven. There is no established “optimal” glucose range for non-diabetic populations, no consensus on what constitutes a problematic glucose spike in someone with normal insulin sensitivity, and no evidence from randomized controlled trials demonstrating that CGM-guided lifestyle changes in healthy individuals produce meaningful long-term health benefits.
Some researchers worry that CGM use in healthy populations may cause more harm than good. The phenomenon of orthosomnia — an unhealthy obsession with achieving perfect sleep data — has a glucose counterpart. Continuous feedback about normal, physiologically appropriate glucose fluctuations can generate anxiety, promote unnecessarily restrictive eating, and, in vulnerable individuals, trigger or exacerbate disordered eating patterns.
Endocrinologists have expressed particular concern about people interpreting normal post-meal glucose elevations as pathological. A blood sugar rise after eating is not inherently harmful — it is a normal physiological response. The danger lies in medicalizing normal variation and driving healthy people toward increasingly restrictive diets in pursuit of a flat glucose line that the human body was never designed to maintain.
The Cost-Benefit Calculus
Consumer CGMs are not cheap. Over-the-counter sensors cost approximately $50-90 per month, while subscription services like Levels and Nutrisense range from $200-400 monthly including sensor costs, app access, and AI-driven insights. Over a year, a CGM wellness habit can easily exceed $3,000 — a significant investment for a tool with unproven benefit in healthy populations.
For specific populations, however, the value proposition is stronger. People with prediabetes — an estimated 98 million American adults — could derive genuine clinical benefit from CGM-guided lifestyle modification, potentially preventing or delaying progression to type 2 diabetes. People with a strong family history of diabetes or metabolic syndrome may similarly benefit from the early metabolic awareness that CGMs provide. The challenge is distinguishing between appropriate use in at-risk populations and excessive use in people whose glucose regulation is already normal.
The Bigger Picture
The CGM-for-all trend reflects a broader shift toward personalized, data-driven health optimization that characterizes the 2026 wellness landscape. It is part of the same movement that has popularized sleep tracking, heart rate variability monitoring, and comprehensive blood biomarker testing. Whether this trend improves population health or simply feeds health anxiety depends on how the technology is deployed — and whether consumers receive appropriate education about what the data means and, crucially, what it does not mean.
For now, the most reasonable position may be cautious optimism. CGMs offer an unprecedented window into individual metabolic responses, and the potential for personalized nutrition is real. But potential is not proof, and consumers should approach continuous glucose monitoring with clear eyes about what the evidence does and does not support — and with a healthy skepticism toward any technology that promises to optimize the fundamentally complex, variable, and imperfect system that is human metabolism.
